#### **Supplementary Information Materials and Methods**

#### **Bacterial strains and growth conditions**

Bacterial strains and plasmids used in this study are listed in *SI Appendix*, Table S3. *P. aeruginosa* strains were grown in or on tryptone soy broth (TSB), lysogeny broth (LB) or Vogel-Bonner medium (VBM) at either 25°C or 37°C with the addition of agar as required. *E. coli* strains were grown in or on LB, TSB, nutrient yeast broth NYB or terrific broth (TB) at 37°C with the addition of agar as required. Media was supplemented with antibiotics where appropriate, *P. aeruginosa*: streptomycin 2000 µg/ml, carbenicillin 50-300 µg/ml, irgasan 25 µg/ml, tetracycline 50-150 µg/ml and gentamycin 40-100 µg/ml or *E. coli*: streptomycin 50 µg/ml, ampicillin 50-100 µg/ml, tetracycline 15 µg/ml and kanamycin 50 µg/ml).

### **DNA** manipulation

DNA isolation was performed using the PureLink Genomic DNA mini kit (Life Technologies). Isolation of plasmid DNA was carried out using the QIAprep spin miniprep kit (Qiagen). Primers used are shown in *SI Appendix*, Table S4 (Sigma). DNA fragments were amplified with either KOD Hot Start DNA Polymerase (Novagen) or standard Taq polymerase (NEB) as described by the manufacturer with the inclusion of Betaine (Sigma) or DMSO (Sigma). Restriction endonucleases were used according to the manufacturer's specifications (Roche). DNA sequencing was performed by GATC Biotech. *P. aeruginosa* deletion mutants were constructed as described previously using 500 bp homologous regions and confirmed with external primers (*SI Appendix*, Table S4) (1). *amrZ* (PA14\_20290) was amplified to construct a C-terminal V5 tag version (from pETDEST42 (Life Technologies)) and ligated into pMMB67HE. For protein purification *amrZ* was amplified and ligated into pET29a in frame with the sequence encoding a C-terminal His<sub>6</sub> tag. The DNA encoding the

C-terminus of VgrG4b (612-808 aa) was synthesised by Invitrogen GeneArt and subcloned into pET28a to construct pET28a-*vgrG4b*. For protein purification *hcp3* was amplified, digested and ligated into pET28a in frame with a His<sub>6</sub> tag. The coding regions of *tssB1*, *tssB2* and *tssB3* were amplified from *Pseudomonas* genomic DNA, *cfp* was amplified from pSEVA237C (de Lorenzo lab collection), 'superfolder' GFP (*sfgfp*) was amplified from mini-CTX-*gfp* (2) using KOD Hot Start DNA polymerase (Novagen). C-terminal fusions of each *tssB* gene with the respective fluorophore were generated by overlapping PCR (*cfp* and *sfgfp*) or by direct in-frame cloning (*venus*) in pME6032 (3).

#### Transposon mutagenesis and screening

Transposon mutagenesis was performed using pBT20 as outlined in (4). Briefly PA14*tssB2*tc::*lacZ* and SM10 $\lambda$ *pir* pBT20 were grown overnight on LB plates, PA14 was then incubated at 43°C for 2 hr to inactivate the restriction system. Bacteria were collected, suspended, OD<sub>600</sub> measured and cells were mixed 1:2, spot plated on LB plates to enable conjugation and incubated. Cells were collected, re-suspended and diluted before being spread plated onto LB agar containing 5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactopyranoside (X-Gal) (Invitrogen), irgasan and gentamycin plates and incubated up to 4 days. Individual colonies were monitored for increased or decreased X-gal colour development twice daily. Transposon mutants of interest were isolated, grown, spot plated and confirmed via galactosidase assay essentially as previously described (5). Transposon insertion sites were mapped via arbitrary PCR (4).

#### **T6SS competition assays**

Competition assays were performed as per (6, 7) except that Top10 pRL662-*gfp* or DH5 $\alpha$  pCR2.1 were used as the prey strains. Briefly overnight cultures were mixed 1:1 and spotted

on LB agar plates for 5 hr. LB agar contained 1 mM IPTG or 1% Arabinose if induction of pAmrZ or pJN105*tssB2-cfp* was required. Spots were recovered, suspended, serial diluted and spotted on to LB, LB X-gal, LB gentamycin and/or PIA plates respectively to enable colony counts as required.

#### Secretion assays

For secretion assays *P. aeruginosa* strains were grown overnight in TSB and subcultured to  $OD_{600}$  0.1 and grown at 37°C or 25°C for 6 or 24 hr, respectively (or as otherwise indicated) with agitation. Culture supernatants were prepared as previously described using trichloroacetic acid precipitation (8). An  $OD_{600}$  equivalent of 0.1 or 1 of cell lysate and supernatant protein samples, respectively were loaded on to SDS-PAGE gels for analysis by western blotting.

### **Protein Purification**

BL21 Star ( $\lambda$ DE3) pAmrZ-His<sub>6</sub> cells were sub-cultured to an OD<sub>600</sub> 0.1 in one litre of NYB and grown at 37°C to an OD<sub>600</sub> 0.7 prior to induction with 1 mM IPTG for 5 hours. Cells were then harvested and frozen at -80°C. The frozen pellet was thawed on ice, suspended in 30 ml of buffer (20 mM Imidazole, 50 mM Tis, 500 mM NaCl) supplemented with cOmplete, EDTA-free protease inhibitor cocktail (Roche) and egg white lysozyme (Sigma) was added to 1 mg/ml and incubated for 45 min prior to probe sonication. The soluble fraction was separated by centrifugation at 18000g for 45 minutes at 4°C and then passed through a syringe driven 0.45 µm filter. Clarified extract was applied to Ni<sup>2+</sup>–NTA columns (Hi-Trap, GE Healthcare) using an ÄKTA Prime. The column was washed with 10-15 column volumes of buffer before switching over to the elution buffer (500 mM Imidazole, 50 mM Tis, 500 mM NaCl). The sample was assessed for purity using SDS-PAGE gels and coomassie staining and the band corresponding to AmrZ-His<sub>6</sub> confirmed with western blot analysis (See Fig. S10). The sample was then diluted into buffer (50 mM Tis, 500 mM NaCl) and quantification was performed using a Pierce BCA protein assay kit following the manufactures instructions and using BSA as standards. *E. coli* B834 (DE3) carrying pET28a-*vgrG4b*, along with *E .coli* BL21 ( $\lambda$ DE3) harbouring pET28a-*hcp3* were grown in terrific broth, induced and harvested. The frozen pellet was suspended in buffer supplemented with cOmplete, EDTA-free protease inhibitor cocktail (Roche) prior to disruption by French press. Clarified extract was applied to Ni<sup>2+</sup>–NTA columns (Hi-Trap, GE Healthcare) using an ÄKTA Prime for purification.

### Western blot analysis

SDS-PAGE and western blotting were performed as described in (6). Briefly, proteins were resolved in 8% (VgrGs, RpoB), 12% (PldA, PldB, RpoB) or 15% (Hcps, TssBs and AmrZ) gels using the Mini-PROTEAN system (Bio-Rad) by electrophoresis and transferred to nitrocellulose membrane (GE Healthcare). Membranes were blocked in 5% milk (Sigma) in Tris-buffered saline pH 8 with 0.1% Tween-20 (TBST) prior to incubation with primary antibodies. Monoclonal antibodies were used at the following dilutions: anti-RNA polymerase (Biolegend) at 1:5000, anti-beta lactamase (Bla) (GeneTex International Corporation) at 1:1000 and anti-V5 (ThermoFisher) at 1:5000. Polyclonal primary antibodies described previously were used at a dilution of 1:1000. These include anti-Hcp1 (8), anti-Hcp2 (9), anti-TssB1 (10), anti-TssB2 (9), anti-VgrG2a and anti-VgrG2b (11). The polyclonal anti-VgrG4b and anti-Hcp3 antibodies were also used at 1.1000. Membranes were washed with TBST before incubation with HRP-conjugated secondary antibodies (Sigma) at a dilution of 1:5000. All monoclonal primary antibodies required anti-mouse secondary antibodies, whereas the polyclonal antibodies all required anti-rabbit secondary antibodies.

Signals were detect using the Novex ECL HRP Chemiluminescent substrate (ThermoFisher) or the Luminata Forte Western HRP substrate (Millipore) using a LAS-3000 Fuji Imager. ECL detection and a white light image of the ladder were taken on a Fuji LAS-3000, separately. Adobe Photoshop was used to adjust the brightness/contrast of the tiff images prior to overlaying and merging of the two layers using the multiply tool followed by merge layers.

### **Antibody Production**

Custom Anti-VgrG4b antibodies were raised against the purified C-terminus of VgrG4b (612-808) with Eurogentec following their immunisation protocols. Antibodies against purified full-length Hcp3 protein was raised similarly.

### **Electrophoretic mobility shift assays**

Electrophoretic mobility shift assays (EMSA) were performed as previously described (8, 9). Using the previous published controls (8, 9). Each reaction contained 40 mM NaCl, 4 mM Tris, 4 mM MgCl<sub>2</sub> (pH 8.0), 4% glycerol (W/V), 100 mg/ml BSA (non-specific protein control), 150 ng/µl poly-deoxy-inosinic-deoxy-cytidylic acid (d[(I-C)]) (Sigma) (non-specific DNA control), 5 nM <sup>32</sup>P-labeled DNA probe and purified AmrZ in the nM range . The 10 µl reactions were incubated at room temperature for 20 min prior to the addition of 2 µl of native loading dye and loading of the entire sample. Reactions were analysed on 4% (w/v) native polyacrylamide gels run at 200 V for 22 minutes prior to drying. Gels were visualised on a Typhoon FLA7000 Phosphorimager (GE Healthcare).

#### **Real Time PCR**

Overnight cultures were subcultured in TSB, grown to early exponential phase and harvested in RNAlater (Ambion). RNA was isolated using TRIzol extraction and purified using the Qiagen RNeasy Mini kit (Qiagen) followed by DNase digestion using PureLink DNase Set (Invitrogen). Purified RNA was stored at -80°C in nuclease-free water. cDNA was synthesised from 200 ng of RNA using SuperScript III Reverse Transcriptase (Invitrogen) and random hexamers (Applied Biosystems) according to the manufacturer's protocol. Real time PCR was performed with Fast SYBR Green Master Mix (Applied Biosystems) or KiCqStart SYBR Green qPCR ReadyMix (Sigma) on an Applied Biosystems StepOnePlus Real-Time PCR machine. The primers used for amplification are shown in *SI Appendix*, Table S4. Real-time analysis was performed on RNA from three independent cultures in duplicate and quantification of *rpoD* gene expression served as an internal control. The relative expression ratios were calculated using the delta-delta method relative to PA14 wildtype or PA14*rsmA* pMMB as indicated.

#### **Microscopy Procedure**

Strains for visualizing coexpression of multiple T6SS systems *in situ* were as follows: PA14*rsmA*, PA14*rsmA* H123 and PA14*rsmA* H13 A2tl (H2-) with combinations of fluorescent fusions pME6032*tssB1-venus*, pJN105*tssB2-cfp*, pJN105*tssB3-cfp* and/or pMMB67*tssB3-sfgfp* (*SI Appendix*, Table S3, S4). *P. aeruginosa* strains for microscopy were grown overnight in TSB with appropriate antibiotic(s) at 37°C, then diluted to an OD<sub>600</sub> = 0.1 in 10 ml fresh TSB plus appropriate antibiotic(s) and grown to OD<sub>600</sub> = 0.3 at 25°C. Plasmid expression was induced with IPTG (50 µg/ml) for strains containing pME6032 or pMMB67HE plasmids, or with arabinose (1%) for strains containing pJN105 plasmids. Cells growing exponentially (OD<sub>600</sub> = 0.8-1.0) were harvested by centrifugation (8000 g, 3 min) and resuspended in PBS to a final OD<sub>600</sub> of 10 units. One microliter of resuspended culture was spotted on a glass-bottomed dish (Ibidi 35 mm µ-dish) and covered with a 1% PBS agarose pad. Cells were imaged using a Zeiss Axiovert 200 inverted microscope fitted with Hamamatsu Flash 4 (2048x2048 pixel) camera for fast low-light imaging, a pE4000 CoolLed Led Illumination source and a 100x 1.4 objective. A 500 nm LED was used to excite TssB1-Venus with an exposure time of 1000 ms using a YFP filter; a 435 nm LED was used to excite TssB2-CFP and TssB3-CFP with exposure times of 300 ms and 100 ms respectively using a CFP filter; and finally, a 500 nm LED was used to excite TssB3-sfGFP with an exposure time of 300 ms using a GFP filter. The LED and dichroic filter sets were selected based upon the spectral profiles for each fluorophore to ensure optimised excitation and emission settings were used for each of the relevant co-expressed fluorescent fusions.

#### **Image analysis**

Microscopy images were analysed in Fiji (10). The Bleach Correction plugin was used on time-lapse image series (15). To determine the number of cells across all fields to be analysed the background was subtracted from brightfield DIC images using a filtered Gaussian blur image with Sigma (radius) = 20 and the 'Image Calculator' Fiji tool. Huang segmentation was then used within the 'Threshold' tool to select all the cells in each field, with the tool 'Analyse Particles' finally used to quantify the number of cells in each field. The range used for 'Analyse Particles' was set at 30-infinity pixels, to ensure that small areas of background brightfield particles (i.e. not cells) were excluded. The number of cells counted by this automated method was initially manually checked on a subset of images to ensure the process was a true reflection of the number of cells present in all subsequent analyses. The number of cells containing foci was then counted manually by using the 'Multi-Point' tool in Fiji. At least 10 separate randomly selected fields of view were analysed for each fluorescent fusion

in PA14*rsmA* which contained between 185 276 and 319 440 total cells or in PA14*rsmA* H123 or PA14*rsmA* H1H3 A2tl (H2-) which contained between 31 666 and 68 208 total cells.

#### **Bioinformatics and statistical analysis**

DNA sequences were retrieved from the Pseudomonas Genome Database (16). Binding motifs were investigated using Mfold (17), FUZZNUC (EMBOSS) and BPROM. DNA and amino acid sequence searches were executed using SMART, InterPsoScan, Pfam and BLAST. Statistical analysis was performed using GraphPad Prism version 5 as indicated in the text.

### **Additional references**

- Vasseur P, Vallet-Gely I, Soscia C, Genin S, & Filloux A (2005) The pel genes of the Pseudomonas aeruginosa PAK strain are involved at early and late stages of biofilm formation. *Microbiology* 151(Pt 3):985-997.
- 2. Hoang TT, Kutchma AJ, Becher A, & Schweizer HP (2000) Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains. *Plasmid* 43(1):59-72.
- Valentini M, Laventie BJ, Moscoso JA, Jenal U, & Filloux A (2016) Correction: The Diguanylate Cyclase HsbD Intersects with the HptB Regulatory Cascade to Control Pseudomonas aeruginosa Biofilm and Motility. *PLoS genetics* 12(11):e1006473.
- 4. Kulasekara HD (2014) Transposon mutagenesis. *Methods in molecular biology* (*Clifton, N.J.*) 1149:501-519.

- 5. Miller JH (1992) A short course in bacterial genetics: a laboratory manual and handbook for Escherichia coli and related bacteria (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
- 6. Hachani A, Allsopp LP, Oduko Y, & Filloux A (2014) The VgrG proteins are "A la carte" delivery systems for bacterial type VI effectors. *The Journal of biological chemistry*.
- 7. Hachani A, Lossi NS, & Filloux A (2013) A visual assay to monitor T6SS-mediated bacterial competition. *Journal of visualized experiments : JoVE* (73):e50103.
- Jones CJ, *et al.* (2014) ChIP-Seq and RNA-Seq reveal an AmrZ-mediated mechanism for cyclic di-GMP synthesis and biofilm development by Pseudomonas aeruginosa. *PLoS pathogens* 10(3):e1003984.
- Xu B & Wozniak DJ (2015) Development of a Novel Method for Analyzing Pseudomonas aeruginosa Twitching Motility and Its Application to Define the AmrZ Regulon. *PloS one* 10(8):e0136426.
- Schindelin J, *et al.* (2012) Fiji: an open-source platform for biological-image analysis.
   *Nature methods* 9(7):676-682.
- Miura K RC, Hiner M, Schindelin J, Rietdorf J. (2012) ImageJ Plugin CorrectBleach V2.0.2.
- 12. Winsor GL, *et al.* (2016) Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database. *Nucleic acids research* 44(D1):D646-653.
- Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic acids research* 31(13):3406-3415.



Figure S1

tap



В

PA14\_20300

PA14\_20290









Figure S4





Figure S6

E. coli prey recovery



В

А



*E. coli prey* and *Pseudomonas* recovered after 5hr of contact time

Figure S7



PA14rsmA

Figure S8



В



Figure S9





#### **Supplementary Figures Legends**

**Fig. S1.** Schematic representation of *P. aeruginosa's* T6SS and *vgrG* clusters from PA14. Gene names or numbers are indicated below each gene cluster. PAO1 gene numbers are indicated above each cluster for the *vgrG* encoding genes for reference (NP = not present). Colored genes indicated T6SS structural components (blue), *vgrGs* (yellow), toxin/immunity pairs (orange/green), other known T6SS genes (dark grey) and not currently associated with the T6SS in light grey. Genes checked via qRT-PCR are indicated by an asterisk. Schematic of upstream regions used for AmrZ binding assays are show and hashed region indicates the sub-fragment bound by AmrZ.

**Fig. S2.** Expression of the H2-T6SS gene cluster in selected PA14 transposon mutants. (*A*) Level of  $\beta$ -galactosidase activity of the A2tc transcriptional fusion in selected mutants are shown. Mutants have been grouped as described in the key. (*B*) Location of transposon insertion in proximity to *amrZ* (*PA14\_20290*). Insertion mutants B1 (14 bp upstream of gene) and B2 (26 bp into gene), which may prevent AmrZ expression (indicated by dotted cross), resulted in increased expression of A2tc. In contrast, insertion mutant W32 (298 bp upstream of *amrZ*) which may increase read through of *amrZ* (indicated by dotted arrow) resulted in reduced expression of A2tc.

**Fig. S3.** AmrZ inversely regulates the H2- and H3-T6SS. (*A*) AmrZ is a negative regulator of the H2-T6SS. Deletion of *amrZ* relieves repression of *tssA2* when grown on agar plates. Beta-galactosidase assay was performed on PA14, PA14A2tc, PA14A2tc *armZ* and PA14A2tc B1 grown in either liquid LB or on LB plates. (*B*) Beta-galactosidase assay showing that overexpression of AmrZ represses transcription of *tssA2* (A2tc) which is absent in the uninduced or vector only (pMMB67HE). Strains were grown in liquid culture. (*C*) AmrZ represses the H2-T6SS (*tssA2*) but activates the H3-T6SS (*tssB3, hcp3* and *tssA3*). qRT-PCR was performed on PA14*rsmA* overexpressing *amrZ* (pAmrZ) and compared to vector control (pMMB). Scatter plot of fold change gene

expression with mean (N = 3). Statistical analysis was performed on the  $\Delta\Delta$ CT values (ANOVA Bonferroni post-test *tssB1* P > 0.05, P < 0.05 for all other genes). (*D*) Fold gene repression of data shown in C.

**Fig. S4. Dissection of AmrZ binding sites.** EMSA was performed using sub fragments of the DNA probes used in figure 3; (*A*)  $tssA1_1$ ,  $tssA1_2$ , (*B*)  $tssA2_1$ ,  $tssA2_2$  and (C)  $tssB3_1$   $tssB3_2$ . In all cases AmrZ only binds to one of the sub fragments from each upstream region. Each reaction contains 5 nM <sup>32</sup>P-labelled DNA and increasing concentrations of purified AmrZ. In all cases, positive (*adcA*) or negative (*algDs*) controls were used as previously published (18, 19). See also Fig. S1 for schematic of AmrZ binding fragments used in this study.

**Fig. S5.** The H2-T6SS is functional in a *rsmA* mutant and Hcp2 depends upon this system for secretion. (*A*) Hcp2 is only faintly detectable when the H2-T6SS is disrupted (PA14*rsmA* A2tl (H2-)) but is still secreted when either the H1-T6SS is deleted (PA14*rsmA* H1-) or the H3-T6SS is disrupted (PA14*rsmA* B3tl (H3-)) after 5 h of growth from an OD<sub>600</sub> of 0.1 at 37 degrees. (*B*) Hcp2 is drastically reduced when the H2-T6SS is disrupted (PA14*rsmA* A2tl (H2-)) but is still secreted when either the H1-T6SS is deleted (PA14*rsmA* A2tl (H2-)) but is still secreted when either the H1-T6SS is deleted (PA14*rsmA* H1-) or the H3-T6SS is disrupted (PA14*rsmA* B3tl (H3-)) after 8 h of growth from an OD<sub>600</sub> of 0.1 at 37 degrees. RNA polymerase (RpoB) is used as a lysis control. (*C*) Deletion of the H1-T6SS cluster including *hcp1* and the H3-T6SS cluster including *hcp3* does not diminish the level of protein detected with the anti-Hcp2 antibody.

**Fig. S6.** PldA and VgrG4b are expressed in a *rsmA* mutant. (*A*) Western blot analysis using anti-TEM to detect PldA-Bla expression, or anti-VgrG4b shows enhanced expression of both proteins in PAO1*rsmA* at 25°C. (*B*) Deletion of *rsmA* enables PldA secretion. Western blot analysis using anti-TEM to detect PldA-Bla expression shows expression in a PA14*rsmA* mutant at 25°C and secretion in a H2-T6SS-dependent manner (A2tl (H2-)). Anti-RNA polymerase (RpoB) is used as a lysis control and anti-Hcp2 as a control for H2-T6SS activity.

**Fig. S7.** *P. aeruginosa* H2-T6SS dependent killing of *E. coli.* (*A*) Serial dilution of the 1:1 bacterial mix including *E. coli* GFP+ and the PA14 attackers as listed. *E. coli* is recovered significantly less when co-incubated with PA14*rsmA* as compared to PA14 and the killing is specifically H2-T6SS dependent as it is not alleviated in either the H1- or H3-T6SS mutants. (*B*) H2-T6SS killing assays demonstrating that the H2-T6SS is as functional in PA14*rsmA* as PA14*rsmA* carrying either pJN105 or pJN105*tssB2-cfp. P. aeruginosa* strains were mixed individually with *E. coli* DH5α carrying pCR2.1 which expresses β-galactosidase. *Pseudomonas* strains were grown in the presence of arabinose 1% prior to the killing assay and arabinose 1% was included in the LB agar for the 5 h contact time to enable constant expression of TssB2-CFP. Recovered bacteria were diluted and spotted on X-gal plates. The level of blue color indicates survival of *E. coli* when the H2-T6SS is disabled (PA14*rsmA* A2tl).

**Fig. S8.** Significantly more H2-T6SS (TssB2-CFP) foci where observed then either H1-T6SS (TssB1-Venus) or H3-T6SS (TssB3-CFP) foci. Quantification of relative numbers of TssB1-Venus, TssB2-CFP and TssB3-CFP foci present in PA14*rsmA* after induction. Cells were grown at 25°C until the OD reached 0.3, at which point expression of the fluorescent fusions was induced by addition of IPTG or arabinose, with cells being harvested during mid-exponential phase and imaged directly. The mean number of foci per total PA14*rsmA* cells + SEM is represented based upon at least 40 separate fields of view captured over two independent days. Total numbers of cells analysed were 284 985 for TssB1-Venus, 185 276 for TssB2-CFP and 319 440 for TssB3-CFP. Statistical analyses were performed using a one-way ANOVA with multiple comparisons (Tukey) comparing all 3 samples (P <0.005).

**Fig. S9.** Differential expression of T6SSs (*A*) Western blot analysis of regulator mutants showing higher levels of expression of H2-T6SS components in PA14 mutants compared to the same mutants in PAK or PAO1. Bacteria were grown at 37°C. (*B*) Western blot analysis showing that strong expression of the H1-T6SS components Hcp1 and TssB1 requires the double *rsmArsmF* mutant. H2-T6SS components have enhanced expression in an *rsmA* mutant but no additional expression was observed in the *rsmArsmF* mutant.

**Fig. S10.** Representative blot for the purification of AmrZ used in EMSAs. (*A*) Coomassie stained SDS-PAGE gel and (*B*) western blot using anti-His antibody to detect AmrZ-His<sub>6</sub>. Fraction 12 and 13 were used for EMSAs.

Table S1. Location of Transposon insertion in mutants with altered transcription of tssA2tc

Table S2. Identification of putative AmrZ binding sites upstream of tssA1, tssA2 and tssB3

Table S3. Strain and Plasmid List

Table S4. Primer List

Mutant	Site of				
code	integration	Gene inserted into/near	PAO1	Gene name	Description
	4747040				Upstream of DNA binding protein (alginate and motility regulator Z), ABC
B1	1/4/943	PA14_20290/PA14_20300	PA3385/PA3384	amrZ(algZ)/phnC	phosphonate transporter ATP-binding protein
B2	1747903	PA14_20290	PA3385	amrZ(algZ)	DNA binding protein (alginate and motility regulator Z)
B5	5789115	PA14_64940/PA14_64950	PA4917/PA4918	pncA	NAD biosynthetic process/Nicotinamidase
B11	3920247	PA14_44030	PA1583	sdhA	Insertion in Succinate dehydrogenase (A subunit), effect likely on <i>sdhB</i> (B subunit)
B15	3923546	PA14_44070	PA1580	gltA	Citrate synthase <i>cisY</i>
B26	5143772	PA14_57760	PA4446	algW	AlgW protein, Alginate pathway
B39	1469468	PA14_17140	PA3649	тисР	Putative membrane-associated zinc metalloprotease
B41	7316	PA14_00060	PA0005	lptA	Putative acyltransferase (lysophosphatidic acid acyltransferase activity)
B46	3824444	PA14_42990	PA1661	tssG2	T6SS component of H2-T6SS, effect may be on PA14_42970 sfa2
B51	1470367	PA14_17140	PA3649	тисР	Putative membrane-associated zinc metalloprotease
B69	4660539	PA14_52570	PA0905	rsmA	Regulator of secondary metabolism (carbon storage regulator)
B100	4826929	PA14_54430/PA14_54450	PA0762/PA0761	algU/nadB	Sigma factor AlgU/AlgT/σ22 / L-aspartate oxidase
B101	4085470	PA14_45960	PA1430	lasR	Transcriptional regulator LasR
W8	1651112	PA14_19120	PA3477	rhlR(sdiA)	RhIR: sdiA acylhomoserine lactone dependent transcriptional regulator
W9	6310464	PA14_70850	PA5368	pstC	ABC transporter/permease
					Upstream of DNA binding protein (alginate and motility regulator Z), ABC
W32	1748225	PA14_20290/PA14_20300	PA3385/PA3384	amrZ(algZ)/phnC	phosphonate transporter ATP-binding protein
W37a	3675920	PA14_41200/PA14_41210	PA1803/PA1804	lon/hupB	Lon protease/DNA-binding protein HU, effect likely on hupB
					Deoxyuridine 5'-triphosphate nucleotidohydrolase, effect likely on downstream
W38b	6263767	PA14_70270	PA5322	dut	gene AlgC
W39	2022161	PA14_23310	PA3164	unknown	EPSP synthase/prephenate dehydrogenase
					PqsA probable coenzyme A ligase/ methylated-DNA-protein-cysteine
W43	4571514	PA14_51430/PA14_51440	PA0996/PA0995	pqsA/ogt	methyltransferase
		PA14 62810		secG	Preprotein translocase subunit SecG, effect on downstream gene(s) encoding tRNA
W44	5604286	1,717_02010	PA4747	500	or transcription elongation/initiation factors
W45	1651117	PA14_19120	PA3477	rhlR(sdiA)	RhIR: SdiA acylhomoserine lactone dependent transcriptional regulator

# Table S1: Location of Transposon insertion in mutants with altered transcription of tssA2tc

Table S2	: Identification	of putative /	Amr7 binding	sites upstream	of tssA1. t	ssA2 and tssB3
Table Jz	identification	n putative i		sites upstream	01 (3371, 6	33AZ and 133D3

Gene	Predicted AmrZ site?	Bp from ideal	3' end relative to ATG (bp)	Strand relative to gene	Location	Putative Site CAAATTGCCATCA	In Sub fragment
tssA1	Yes	5	-156	-ve		CACAACGCCACTA	tssA1_1
tssA1	Yes	5	-110	+ve	Overlapping predicted-35	AATTTTGCCAACC	tssA1_2
tssA1	Yes	5	-86	+ve	Overlapping predicted -10	CCGATATTCATCA	tssA1_2
tssA2	Yes	1	-265	+ve	Close to predicted -35	CAAATGGCCATCA	tssA2_1
tssA2	Yes	4	-243	-ve	Overlapping predicted -10	GCTATAGCCATCA	tssA2_2
tssB3	Yes	4	-436	-ve		CCAATCGCGAGCA	tssA3_1
tssB3	Yes	5	-231	+ve	Close to predicted -35	AGAATTTCCGACA	tssA3_2

Note: Fragment in red text is bo	und by AmrZ in <i>SI appendix</i> , Fig. S4.
Hotel Hughlene in rea text is bo	

#### Table S3: Strain and Plasmid list

Strain/Plasmid Strain E. coli DH5a Top10 CC118λpir SM10λpir BL21 Star (ADE3) B834 (λDE3) 1047 P. aeruginosa PA14 PAO1 РАК PA14 A1tl PA14 A2tc PA14 A2tl PA14 B3tl

PA14 A1tl rsmA PA14 A2tl rsmA PA14 B3tl rsmA PA14 A2tc amrZ PA14rsmA PA14amrZ PA14rsmAamrZ PA14rsmF PA14rsmArsmF PA14rsmA H1-PA14rsmA H13-PA14rsmA H13- A2tl (H2-) PA14rsmA H123 PA14 hcp3v5 PA14rsmA hcp3v5 PA14rsmA hcn3v5 B3tl (H3-) . PA14pldB-bla PA14rsmA pldB-bla PA14 pldA-bla . PA14rsmA pldA-bla PA14rsmA pldA-bla A2tl (H2-) PAO1rsmA PAO1rsmA tssB2 (H2-) PAO1 pldA-bla PAO1rsmA pldA-bla PAO1rsmA pldA-bla tssB2 (H2-) PAO1rsmA pldA-bla vgrG4b PAKrsmA PAKretS PAO1*rsmA* PAO1retS PA14retS

#### Plasmids

pCR-BluntII-TOPO . pKNG101 pRK2013 . pRL662*-gfp* pBT20 pKNG101-*tssA1 ::lacZ* tl . pKNG101*-tssA2 ::lacZ* tc . pKNG101*-tssA2 ::lacZ* tl pKNG101*-tssB3 ::lacZ* tl . pKNG101-rsmA . pKNG101-amrZ pKNG101-pldA-bla pKNG101-pldB-bla pKNG101-H1-T6SS pKNG101-H2-T6SS pKNG101-tssB2 . pKNG101-H3-T6SS pKNG101-retS pKNG101-hcp3v5 pKNG101-vgrG4b pET28a pET28a-vgrG4b (612-808) pET28a-hcp3 pMMB67HE pAmrZv5 pET29a pAmrZhi pME6032::VenusC pME6032tssB1-venus . pJN105 pJN105tssB2-cfp pJN105tssB3-cfp pMMB67HEtssB3 -sfgfp pSEVA237C mini-CTX-gfp pCR2.1

#### **Relevant Characteristics**

$$\label{eq:resonance} \begin{split} &F^{-}endA1\ glnV44\ thi-1\ recA1\ relA1\ gyrA96\ deoR\ nupG\ purB20\ \varphi80dlacZ\DeltaM15\ \Delta(lacZYA-argF)U169,\ hsdR17\ (r_{\kappa}^{-}m_{\kappa}^{+}),\ \lambda\\ &F^{-}mcrA\ \Delta(mrr\ -hsdRMS\ -mcrBC)\ \varphi80lacZ\DeltaM15\ DlacX74\ nupG\ recA1\ araD139\ \Delta(ara\ -leu)7697\ galE15\ galK16\ rpsL(Str^{8})\ endA1\ \lambda\\ &Host strain\ for\ pKNG101\ replication;\ \Delta(ara\ leu)\ araD\ DlacX74\ galE\ galK\ -phoA\ 20\ thi-1\ rpsE\ rpoB\ argE\ (Am)\ recA1\ Rfr\ \lambda pir\\ &Host\ strain\ for\ pKNG101\ replication;\ thi-1\ thr\ leu\ tonA\ lacY\ supE\ recA::RP4-2-Tc::Mu\ \lambda pir,\ KmR\\ &F^{-}ompT\ hsdS_{8}(r_{B}\ -m_{B}\ )\ gal\ dcm\ met\ (\lambda DE3)\\ &Host\ strain\ for\ pRX2013 \end{split}$$

Wild type Wild type Wild type PA14tssA1 :: lacZ tl (tssA1 lacZ translational fusion (PA14\_00990)) PA14tssA2 :: lacZ tc (tssA2 lacZ transcriptional fusion (PA14 43050)) PA14tssA2 :: JacZ tl (tssA2 lacZ translational fusion (PA14\_43050)) PA14tssB3 :: lacZ tl (tssB3 lacZ translational fusion (PA14\_34070)) PA14tssA1 :: JacZ tl rsmA deletion mutant (Also refered to as PA14rsmA A1tl (H1-)) PA14tssA2::lacZ tl rsmA deletion mutant (Also refered to as PA14rsmA A2tl (H2-) ) PA14tssB3 ::lacZ tl rsmA deletion mutant (Also refered to as PA14rsmA B3tl (H3-)) PA14tssA2 :: lacZ tc amrZ deletion mutant PA14rsmA (PA14\_52570) deletion mutant PA14amrZ (PA14\_20290) deletion mutant PA14rsmA (PA14 52570) and amrZ (PA14 20290) deletion mutant PA14rsmF (PA14\_68470) deletion mutant PA14rsmA and rsmF deletion mutant PA14rsmA and H1-T6SS (tagO1-yarG1b) deletion mutant PA14rsmA, deletion of H1-T6SS (tagQ1 -vgrG1b) and H3-T6SS (tssB3 -clpV3) PA14 rsmA A2tl, deletion of H1-T6SS (tagQ1 -vgrG1b) and H3-T6SS (tssB3 -clpV3) PA14rsmA, deletion of H1-T6SS (tagQ1 -vgrG1b), H2-T6SS (tssA2-clpV2) and H3-T6SS (tssB3 -clpV3) PA14 hcp3v5 (PA14\_34030) PA14rsmA hcp3v5 PA14rsmA B3tl (H3-) hcp3v5 PA14 pldB fusion with Bla Beta Lactamase PA14rsmA deletion mutant, pldB fusion with Bla Beta Lactamase PA14 pldA fusion with Bla Beta Lactamase PA14rsmA pldA fusion with Bla Beta Lactamase PA14rsmA pldA fusion with Bla Beta Lactamase PAO1rsmA deletion mutant PAO1rsmA tssB2 (H2-) deletion mutant PAO1 pldA fusion with Bla Beta Lactamase PAO1rsmA pldA fusion with Bla Beta Lactamase PAO1rsmA tssB2 (H2-) pldA fusion with Bla Beta Lactamase PAO1rsmA pldA fusion with Bla Beta Lactamase, deletion of vgrG4b (PA3486) PAKrsmA deletion mutant PAKretS deletion mutant PAO1rsmA deletion mutant PAO1retS deletion mutant PA14rsmA deletion mutant

Blunt cloning vector, ZeoR/KmR Suicide vector, sacB, StrR Tra+, Mob+, KmR Broad host range vector derived from pBBR1MCS-5 expressing GFP, GmR For mariner transposon mutagenesis, GmR/AmpR tssA1 ::lacZ tl (PA14\_00990) translational fusion, StrR tssA2 ::lacZ tc (PA14\_43050) transcriptional fusion, StrR tssA2 ::lacZ tl (PA14\_43050) translational fusion, StrR tssB3 ::lacZ tl (PA14\_34070) translational fusion, StrR rsmA (PA14\_52570) mutator, StrR amrZ (PA14\_20290) mutator, StrR pldA fusion with Bla Beta Lactamase, StrR pldB fusion with Bla Beta Lactamase, StrR H1-T6SS (PA0070-PA0095) mutator, StrR H2-T6SS (PA1656-PA1662) mutator, StrR tssB2 (PA14\_43040) mutator, StrR H3-T6SS (PA2365-PA2371) mutator, StrR retS (PA14\_64230) mutator, StrR hcp3 (PA14 34030) mutator for addtion of v5 tag, StrR vgrG4b (PA3486) mutator, StrR Expression vector, KmR Sequence encoding the C-terminus of varG4b (PA3486) was synthesised by Invitrogen GeneArt and subclone pET28a, KmR pET28a-hcp3 (PA2367) cloned in frame with a His6 tag, KmR Broad host range expression vector with tac promoter (MCS HindIII-EcoRI), AmpR pMME67HE-amrZ (PA14\_20290) amplified with a V5 tag, AmpR Expression vector, KmR pET29a-amrZ (PA14\_20290) cloned in frame with a His<sub>6</sub> tag, KmR Broad host range expression vector, for fusion of Venus at C-terminus IPTG induction, TetR Strain expressing TssB1-Venus (PA0083) under IPTG induction, TetR Broad host range expression vector, araC-PBAD cassette cloned in pBBR1MCS-5, GmR Strain expressing TssB2-CFP (PA1657) under arabinose induction, GmR Strain expressing TssB3-CFP (PA2365) under arabinose induction. GmR Strain expressing TssB3-GFP (PA2365) under IPTG induction, AmpR Cloning vector with pBBR1 ORI containing cfp coding region, KmR Plasmid for integration of afp fusions into the att site of the P. aeruainosa chromosome. TetR

Constituative expression of β-Galactosidase, self ligated, AmpR/KmR

tide Sequence (5'-3') TGAGGTAGTACACCCCGTCGCG TGGTCTGGTGTCAAAAATAACTAAGCGGCCGTCCGGGCCAACG GCGCGCCCGGGCGGGCCCTTGATCGCCTTCATG TGGTCTGCTGGTGGTGGTGGTCTG GCGCGGGATCCGTCCGGCAGGACCCAGTCGTTG GACGGCCAGTGAATCCGTAATCATGGTCACGGTGACGATCTCCCTATCATCG GEGEGGGATECATGGAEGEGGGGGGGCGCTGAEGTTTGG CCTCTAGCTAGACAGCAATCCCAGTCCGGCCAGCAAA TRATTATIANIACLETARIA NA NA SUNTECANTECANTECON TUBE TAGETETANIA CARCENTATIA TAGETETANIA CARCENTATIAN GEGEGGGGGCE CINTETGETICETTGGCI AGGGGTG CARTANTECTER CARGANTA GEGEGGGATECTECANTITECANTGA GACGGCCAGTGAATCCGTAATCATGGTCATCCTAACCCTTCAATGCACAC CCTAACAATTCTCATGCCAGTG CATTACCAGTTGGTCTGGTGTCAAAAATAACCCTCTTCCCGGAGAAGCCGCC GCGCGGGGCCCTCGGTGAAGCTGTTCATGTCGA GECCGGGGCCCTCGGTGAAGCTGTCATGTCGA GCCCGGGGCCCTCGGTGAAGCTGTCATGTCGA CCCAGAGGTACTTGGAAGTGG GCCCGGGATCCATCGTTGACCAGTCGCATTTCC GACGGCCAGTGAATCCGTATCATGGTCATGGC AATCCCTGCAACTGGAAATGCTG GGETGACTECGATGEAA ATGACCATGATTACGGATTCAC TTATTTTTGACACCAGACC GTGCTGCAAGGCGATTAAGT GGGGGATGTGCTGCAAGGCGATTAAG ACGGTTTCCATATGGGGATT GGCCACGCGTCGACTAGTACNNNNNNNNNAGAG GGCCACGCGTCGACTAGTACNNNNNNNNNACGCC GGCCACGCGTCGACTAGTACNNNNNNNNNNAGATAT GGCCACGCGTCGACTAGTACSNNNNNNNSNSSSGCG TATAATGTGTGGAATTGTGAGCGG GGCCACGCGTCGACTAGTAC ACAGGAAACAGGACTCTAGAGG ATATAGGGCCCCTTCAAGATCCTCGGGCCGATC ATATAGGECET TOMAGTICE TOTAGE CONCERNMENT TGACGECGAAATCAGGATTCETTTETE ATGETEGATTTCGGEGTCAACGEGECGA ATATACCCGGGGCAACTGTCGATCCTTCGTCCG GTCGAGTTCGCCGGCAAGTACAAC CTTTCGGTATGGCCGCACTCAGG ATATAGGGCCCGGCGGTTGACCAGGTTGAACTG TCAGGCCTGTGGGCGCATACATTGAAC ATGCGCCCCACAGGCCTGAGGCCCCAAG ATATACCCGGGGGCGCAGCACTATCCAGATAG CTGGGTCAGGCCGCGGCGATG CCGTAGGCCGAGAGGTGTGTGG ATGATGGGCCCCGCTCCAGGTTGAGCTGATTGAGGC CAACTCGTCGAAACCCATGTTCCGCGT ATGGGTTTCGACGAGTTGAAGACGGCACCG ATCATGGATCCTAATCGCGTTCGGCCTGCTG CGGCCCAGTGACAGAGATCG ATGGTCAACGACATGGAGCTGGAG TCAGTICTCGAAGGCCTGATCGGCCTCG TCAGGCCTTCAGAACTGAACGGCCTCG TCAGGCCTTCAGAACTGAAGCGGCGCA GGTGGCGTTCAACAGTTCCATGTC ATCAGCCTGACCACCCTCGACGAC AGAACGGCTTGAAGGGAACGAACT GACTGGTTGAAAATCCTGGAAAAC AGGAGGCGGTTCGCCTGAGGTGGGTGC CAACACGGTATAGGGGTTGTG GAATTGTTAAGATATTCATTGGCGCAC TCGAGCAGCAGCAGGGTTCCGCCATCCGCG ATTTCCGACATATGGTGAAACATC TGCTGATCAGAAGCGCAGCTCGACGTT CTGCGCTTCTGATCAGCATCAACCTCT GTGAATGGCACGAATAAATAGTTCATA AACTGCTGCCGGTAGTCGCGGCGGTA CTGACAGTTCCCCTGCCGTTAACGCCG GCGCGGGATCCGGATCAGCGTCCATGTCATG ULULUUUAILLGGATCAGCGTCCATGTCATG TCAGCCGAAAGACCATGCTTTTC ATGGCCAAAGACGCCTGAGCCACCCCT GCGCGGGGCCTGGAGACGTATTGCATCAGC CAGGCGATGCGGGAAGTCGAAA TCTGCCACTTGGCGAACTGC ACCGAACAGATCTACGTGCA AAGCATCGCACAGCGGCCAGCCT AGGCTGGCCGCTGTGCGATG CCCTTTTTACCAATGCTTAATCAGTG CATTGGTANAAAGGTTTTGATGG CATTGGTANAAAGGGTTTTGATGG TCATGTGGGATGCTTTCCTTACCAATG ATCGCACATGANAAGGGTTTTGAT TACCTTCGCAGTTTGGCATG CAGGATAAAGCCGATGGTGC CAAGATCGAGGGGCTCGAAG GTCMMATTTTACGGTGGACGCGGCCAGCCTGGAAG GCATCGCTCAGTCCACCGTTACCAATGCTTAATCAG ACAGAGCACGGCCCAAAGTC ATGACTTGCGGGAAAAGCGG ACGGCGGCAGAATGGTCTTTT CTTCCAGGCTGGCCGCGTCCACCGTAAGATTTTGAC CTGATTAAGCATTGGTAACGGTGGACTGAGCGATGG CCACGCCAACTGGAGGTC CGCAGCAACGTTGAACATCCGCTGTCC ATGTTCAACGTTGCTGCGAAGGCGACC ATAGCCGATGCGGTTGTC GCCTACGCCACCTTCCTCGA GCGCATGCAGCGTCAGGCTG GCGCGACTAGTGCCTGATGATCGACAAGAGCGG TCAGGAGGGCCGTACCACGGCGAAGTCC GTGGTACGGCCCTCCTGAGGGCAGCGAC GCGCCACTAGTGCCATGCGCTTGCGGTCG GAGGAGGCCAGCTTCATCGTCATG TGCTGCACGTTGTCGCTCTG GCTAATCTAGATAACAGGAGGAATTAACCATGCGCCCACTGAAACAGGCAACTCCTACCT GCTAAGGATCCTCACGTAGAATCGAGACCGAGGAGAGGGGTTAGGGATAGGCTTACCGGCCTGGGCCAGCTCCGCA

GTCAGTCATATGCGCCCACTGAAACAGGCAACTCCTACCT ACTGACCTCGAGTGCGGCCGCGGGCCTGGGCCAGCTCCGC/

GAGCATATGGATGCGATCATTCTCGATTTC AAAGGATCCTCACTTGACCAACTGGTTG CAAACGGCCGGAACTTCCCT

САААСGGCCGGAACTTCCCT ТАGTTCGGTCCATAGAATTCAAG GGTAGTCCGTCGCACAAAS GCGCTTCTTCGTCGTCGTCTC TCTTTTAAAGATTGTCCGATCTGC GGAATCCACTGTTGTAGATCC GGAATCCACTGTTGTCTGCCTTAT

#### Description

tsA1\_Left\_screening (PA14\_00990) Right pool amplification of tsA14 (PA14\_00990) transcriptional/transistional fusion Right pool amplification of tsA14 (PA14\_00990) transcriptional/transistional fusion tsA1\_right\_screening (PA14\_00990) Right pool amplification of tsA1 (PA14\_00990) transistional fusion Right pool amplification of tsA1 (PA14\_00990) transistional fusion

Left pool of S00 bp for tssA2 (PA14\_4050) transcriptional fusion: BamH1 site for ptNGI01 Left pool of S00 bp for tssA2 (PA14\_4050) replacement Lac2 with 21 bases from the RBS region pQF90 tssA2\_Left\_screening transcriptional fusion (PA14\_4050) Right pool of S00 bp for tssA2 (PA14\_4050) replacement with Lac2: Mail Right pool of S00 bp for tssA2 (PA14\_4050) replacement with Lac2: Mail Site tssA2\_Right\_screening (PA14\_4050) Left pool of S00 bp for tssA2 (PA14\_4050) replacement with Lac2: Mail Site Left pool of S00 bp for tssA2 (PA14\_4050) replacement with Lac2 Left pool of S00 bp for tssA2 (PA14\_4050) replacement with Lac2 Left pool of S00 bp for tssA2 (PA14\_4050) replacement with Lac2

Right pool of 500 bp for ts83 (PA14\_34070) replacement with Lac2 Right pool of 500 bp for ts83 (PA14\_34070) replacement with Lac2: Smal site ts83, Right, screening (PA14\_34070) Left pool of 500 bp for ts838 (PA14\_34070) replacement with Lac2: BamHi site Left pool of 500 bp for ts838 (PA14\_34070) replacement with Lac2 ts83\_Left\_screening (PA14\_34070)

Amplification of entire lac2 gene from mini-CTX-lac2 Amplification of entire lac2 gene from mini-CTX-lac2 with BBSpQF50 Amplification of entire lac2 gene from mini-CTX-lac2 lac2B\_screening lac2T\_Screening lac2T\_Screening

Round 1 arbitrary primers transposon identification Round 1 arbitrary primers transposon identification Round 1 arbitrary primers transposin identification Round 1 arbitrary primers transposin identification BT20 transposon specific primers Rod.1-TnM20 round 1 arbitrary primers Round 2 common primer which hybridizes in to round 1 round 2 arbitrary primers For pBT20 transposon

Primer 1 rsmA deletion mutant Primer 2 rsmA deletion mutant Primer 3 rsmA deletion mutant Primer 4 rsmA deletion mutant Primer 5 screening for deletion mutant of rsmA

Primer 1 amr/2/alg2 (PA14, 20250) deletion mutant Primer 2 amr/2/alg2 (PA14, 20230) deletion mutant Primer 3 amr/2/alg2 (PA14, 20230) deletion mutant Primer 4 amr/2/alg2 (PA14, 20230) deletion mutant d Primer 6 screening for deletion mutant of amr/2/alg2 (PA14, 20230) Primer 6 screening for deletion mutant of amr/2/alg2 (PA14, 20230)

Primer 1 rsmF gene deletion Primer 2 rsmF gene deletion Primer 3 rsmF gene deletion Primer 4 rsmF gene deletion Primer 5 screening for deletion mutant of rsmF Primer 6 screening for deletion mutant of rsmF

Primer 1 deletion of H1-T6SS cluster (tagQ1-ygrG1b) Primer 2 deletion of H1-T6SS cluster (tagQ1-ygrG1b) Primer 3 deletion of H1-T6SS cluster (tagQ1-ygrG1b) Primer 4 deletion of H1-T6SS cluster (tagQ1-ygrG1b) Primer 6 screening for deletion mutant of H1-T6SS cluster (tagQ1-ygrG1b)

Primer 1 deletion of H2-T655 cluster (tssA2-clpV2) Primer 5 screening for deletion mutant of H2-T655 cluster (tssA2-clpV2) Primer 5 screening for deletion mutant of H2-T655 cluster (tssA2-clpV2)

Primer I deletion of H3-T655 cluster (tssB3-cjpV3) Primer 2 deletion of H3-T655 cluster (tssB3-cjpV3) Primer 3 deletion of H3-T655 cluster (tssB3-cjpV3) Primer 4 deletion of H3-T655 cluster (tssB3-cjpV3) Primer 6 screening for deletion mutant of H3-T655 (tssB3-cjpV3) Primer 6 screening for deletion mutant of H3-T655 (tssB3-cjpV3)

Primer 1 VS insertion to Hcp3 in PA14 Primer 2 VS insertion to Hcp3 in PA14 Primer 3 VS insertion to Hcp3 in PA14 Primer 4 VS insertion to Hcp3 in PA14 Primer 5 screening for VS insertion to Hcp3 in PA14 Primer 6 screening for VS insertion to Hcp3 in PA14

Primer 1 tssB2 gene deletion Primer 2 tssB2 gene deletion Primer 3 tssB2 gene deletion Primer 4 tssB2 gene deletion Primer 5 screening for deletion mutant of tssB Primer 6 screening for deletion mutant of tssB

External of pldA-Bla shuttle up PldA w/o STOP + overhang vgrG2b-linker, F PldA w/o STOP + overhang vgrG2b-linker, R bla + overhang downstream of pldA, F bla + overhang downstream of pldA, F

bia + overhang downstream of pidA, K bia + overhang downstream of pidA, F bia & RBS of tilSa, R bia & RBS of tilSa, F Cloning whole tilSa after pidA-Bia shuttle External downstream of pidA-Bia shuttle

Primer 1 PidB-Bla fusion Primer 2 PidB-Bla fusion Primer 3 PidB-Bla fusion Primer 4 PidB-Bla fusion Primer 5 PidB-Bla fusion Primer 5 PidB-Bla fusion Primer 7 PidB-Bla fusion Primer 7 Pimer to amplify upsteam region for pidB-bla PA14 Primer 8 Primer to amplify downsteam region for pidB-bla PA14

Primer 1 vgrG4b gene deletion Primer 2 vgrG4b gene deletion Primer 3 vgrG4b gene deletion Primer 4 vgrG4b gene deletion Primer 5 vzreening for deletion mutant of vgrG4b Primer 6 szreening for deletion mutant of vgrG4b

Primer 1 retS gene deletion Primer 2 retS gene deletion Primer 3 retS gene deletion Primer 4 retS gene deletion Primer 5 screening for deletion mutant of retS Primer 6 screening for deletion mutant of retS

Forward primer RBS with Xbal site for cloning into pMMB67HE Reverse primer VS tag with BamHI site

Primer to amplify AmrZ and cut with Ndel for cloning into pET29a Primer to amplify AmrZ and cut with XhoI for cloning into pET29a

Primer to amplify hcp3 and cut with Ndel for cloning Primer to amplify hcp3 and cut with BamHI for cloning

algD, negative control AmrZ binding assay algD, negative control AmrZ binding assay PA4843 positive control AmrZ binding assay PA4843 positive control AmrZ binding assay tssA1F promoter region to test AmrZ binding tssA1F promoter region to test AmrZ binding

OAL2989	tssA2_R
OAL3088	tssB3_F
OAL2991	tssB3_R
OAL3091	algB68
OAL3092	algB69
OAL3093	algD71
OAL3094	algD73
OAL4016	tssA1amrZ75R
OAL4017	tssA1amr293F
OAL4022	tccA2amr7110E
OAL4023	tssR3amr7200R
OAL4025	tssB3amrZ200F
RT PCR	
OAL2134	vgrG2a F
OAL2135	vgrG2a R
OAL536	vgrG2b F
OAL537	vgrG2b R
OAL3042	VgrGD F
OAL3043	vgrG5 E
OAL3030	verG5 R
OAL3034	vgrG4b F
OAL3035	vgrG4b R
OAL2136	tle4(tplE) F
OAL2137	tle4(tplE) R
OAL3038	tle3 F
OAL3039	tle3 R
OAL3044	PA14_69520 F
OAL3045	nldB(tle5h) E
OAL3032	pldB(tle5b) R
OAL3036	pldA(tle5a) F
OAL3037	pldA(tle5a) R
OAL1029	tssB1 F
OAL1030	tssB1 R
OAL511	tssA2 F
OAL512	tssA2 R
OAL3048	tssB3 F
OAL2049	hea2 E
OAL3029	hcp3 R
OAL3046	tssA3 F
OAL3047	tssA3 R
OAL4035	tssA1 F
OAL4036	tssA1 R
OAL4037	tssB2 F
OAL4038	tssB2 R
OAL3022	vgrG3 F
OAL3023	vgrG3 R
OAL820	rpoD P
Microscropy plasmids	TPOD K
pME6032tssB1-venus	
OAL2946	5' tssB1
OAL2947	3' tssB1
pJN105tssB2-CFP	
OAL3403	5' tssB2
UAL3404	3' tssB2
DINITOSTSSB3-CFD	E <sup>1</sup> tooP2
OAL3405 OAL3406	3' tssB3
OAL3439	CFP linker F new
OAL3440	CFP_linker_R_new
pMMB67HEtssB3-GFP	
OAL3260	tssB3_sfGFP_F
OAL1686	5'sfGFP
OAL1687	3'stGFP

CCCTCHTTGGAAHTTICCTATTC CGACTGGATGAACTGACCGGG CCCTGGTCGGTCACTGGGGA CGCATGGCGACTGCAGGGGTCG ACCGTTGGTCGCTGCAGATGGGTTCTG ACCGTCGGTGCGCAATGGCTTGCCA TGCCCACAGATTTGCCAA GGCCACAGAGTTTGCCAA GTATGGATGGCCGGCGGCGCG GGGCAGCCGTGCCAACTCGAC TTCGACACCGTTCGATGA GTCATCAGTTTCACCACACC GGAGCCGGGAAAGACGTT AGGCTTCCCCGAACTCGTT GGCATTGCTGCAGAAAGAAAC TCAGTGCGCATCGGTTTT AGCCATCGCCCAGAAGAT CGTAGAGCCGATACGGTTG CTCCARGGTANGCAGCACCA TICCATAGCTGACGTGTG CUAITCTGTTTGTCCGAGG GCTGACGATGTTATCCATC TCTACATCCGGCGCAAGTT CCGCGGTCTTGTGAGTAT GGTACGGGGGAAAGACCAGT GGTACGGGGGAAAGACCAGT AACTCGCCCGTGATCAT AAGCCCCAGGTGATGATGT CCTCCAAGGTACGATCGT GCCTCAAGGTACCCATCGT GCCTCAAGGTACCCATCGT GCCTCAAGGTACCGTCTCGAA GTCCAGGGTAAGGAGCACAA GCCTTCAACGTACCGAACCGT GAAGTCGTCCATGGCCCTCTAC GATTGACTCGGGCCCTCTAC GATGCACTGGGCCCTCTAC GAAGCACAACGCTGGAC GCAGCTCCTTCTTCGAATG GATCATGCCCTTCATCGCT TGGTAAGTGCGCTGCAACCC GCAGGCTGCTGCTGCACCC TGCTGCAGCGACGCTCCT GCASGCTGCTGTCGTCCT CTGCTGCAGAGCAACGTC GATAGACGCCGTCCCAGTA GCCAAAGAAGGCTCGGTAG CTCAACGGCAGTCCGATAG CGACAGTCTGGATGTGAAG CCACCGTCAGCTCGAAGT AGGCCGTGAGCAGGGATAC TCCCCATGTCGTTGATCATG

CCCTCTTTGGGAATTTTCCTATTC

# GCGAGCTCATGGGAAGCACTACCAGC GGGGTACCCGCGCCTGCGGCTCGTCGTC

GGCGCCCCGGGTCAATTCTCAAGGAGAAAAAGCC

GCGCCCCGGGTTGCATCGGAGTCAGCCGCC CCTCCTCCTGCTGCGGCGGCCGGCTGGTCGGCC GCAGCAGCAGGAGGAAGGAATGGTGAGCAAGGGCGA GCGCGTCTAGATTACTTATACAGCTCGTCCATGCC

GCATCGGAGTCAGCCGCC GCAGCAGCAGGAGGAGGAATGCGTAAAGGCGAAGAA CCTAGTTCATTACTTATACAGCTC

tsx32R promoter region to test Amr2 binding tss352 promoter region to test Amr2 binding tss358 promoter region to test Amr2 binding alg8 negative control for Amr2 binding assay longer fragment alg0 positive control for Amr2 binding assay longer fragment alg0 positive control for Amr2 binding assay longer fragment alg0 positive control for Amr2 binding assay longer fragment alg0 positive control for Amr2 binding assay longer fragment alg0 positive control for Amr2 binding assay longer fragment use with 0A12986 to amplify a 35 b pfragment with 1 putative amr2 binding site Use with 0A12986 to amplify a 34 bp fragment with 1 putative amr2 binding site Use with 0A12986 to amplify a 30 bp fragment with 1 putative amr2 binding site Use with 0A12980 to amplify a 30 bp fragment with 1 putative amr2 binding site Use with 0A12991 to amplify a 200 bp fragment with 1 putative amr2 binding site Use with 0A12991 to amplify a 200 bp fragment with 1 putative amr2 binding site Use with 0A12991 to amplify a 200 bp fragment with 1 putative amr2 binding site

Use with OAL3088 to amplify a 200 bp fragment with 1 putati use with OAL3088 to amplify a 200 bp fragment with 1 putati qRT-PCR (PA14\_44900/PA1511) qRT-PCR (Wa16\_44000/PA1511) qRT-PCR WgCD5 (PA14\_02320)/PA0262) qRT-PCR WgCD5 (PA14\_02520) qRT-PCR WgCD5 (PA14\_02500) qRT-PCR WgCD5 (PA14\_0500) qRT-P qRT-PCR tissA1 (PAL4\_34140)PA2360) qRT-PCR tissA1 (PAL4\_3098) 100 bp qRT-PCR tissA1 (PA0082/PAL4\_0099) 100 bp qRT-PCR tissA1 (PA0082/PAL4\_0099) 100 bp qRT-PCR tissA1 (PA1565/PAL4\_43050) 96 bp qRT-PCR tissA1 (PA1373/PAL4\_33060) 114 bp qRT-PCR tissA1 (PA1373/PA14\_33060) 114 bp qRT-PCR tissA1 (PA1374) qRT-PC

## Cloning tssB1 into pME6032-Cterm-venus Cloning tssB1 into pME6032-Cterm-venus

To amplify tss82 (PA1657) with a linker to generate overlapping product with CFP linker To amplify tss82 (PA1657) with a linker to generate overlapping product with CFP linker

To amplify tssB3 (PA2365) with a linker to generate overlapping product with CFP linker To amplify tssB3 (PA2365) with a linker to generate overlapping product with CFP linker Generation of Cterm CFP fusion with linker using pSFVA327C as template Generation of Cterm CFP fusion with linker using pSFVA237C as template

5' tssB3 coding region to fuse with sfGFP 5' primer sfGFP with linker 3' primer sfGFP